Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.57 |
| ▸ | HTR1D | P28221 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6580144 | 0.99 | HTR6 (0.56) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| SCHEMBL6575496 | 0.91 | HTR6 (0.56) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| Hydrochloric Acid SCHEMBL6575484 | 0.90 | HTR6 (0.54) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| SCHEMBL6580300 | 0.87 | HTR6 (0.51) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| SCHEMBL6577240 | 0.86 | HTR6 (0.53) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| Hydrochloric Acid SCHEMBL6575494 | 0.86 | HTR6 (0.50) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| Hydrochloric Acid SCHEMBL6577908 | 0.85 | HTR6 (0.52) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| SCHEMBL3410920 | 0.85 | MAPT (0.64) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| SCHEMBL6577979 | 0.82 | HTR6 (0.66) | HTR6HTR1DHSD17B10HTR7CYP1A2 | |
| SCHEMBL7886752 | 0.81 | HTR1D (0.71) | HTR6HTR1DHSD17B10HTR7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6565829-B2 | Psychological disorders; central nervous system disorders | PHARMACIA & UPJOHN COMPANY | 2003-05-20 | — | — | US | claimed |
| US-20030060498-A1 | 5-arylsulfonyl indoles useful for treating disease | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | claimed |
| EP-1411925-A1 | 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6565829-B2 | Psychological disorders; central nervous system disorders | PHARMACIA & UPJOHN COMPANY | 2003-05-20 | — | — | US | disclosed |
| US-20030060498-A1 | 5-arylsulfonyl indoles useful for treating disease | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2003011284-A1 | 5-ARYLSULFONYL INDOLES HAVING 5-HT6 RECEPTOR AFFINITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060498-A1 | 5-arylsulfonyl indoles useful for treating disease | IDO1, HTR5A, IDO2 | HTR6 14/4885HTR1D 33/4885HSD17B10 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.